Champions Oncology Q4 revenue beats analyst expectations

Champions Oncology

23/07/2025 21:16

Overview

Champions Oncology fiscal Q4 revenue beats analyst expectations, per LSEG data

Adjusted EBITDA for fiscal Q4 beats consensus, reflecting operational efficiency

Fiscal 2025 revenue grows 14% yr/yr, driven by new data business

Outlook

Champions Oncology expects continued revenue growth in fiscal 2026

Company confident in further monetization of data offering

Champions sees strong pipeline heading into fiscal 2026

Result Drivers

DATA BUSINESS - New high-margin data business contributed $4.7 mln to annual revenue, driving overall growth

OPERATIONAL EFFICIENCY - Disciplined execution and operational improvements led to record adjusted EBITDA and reduced costs

MARKETING EXPENSES - Increased sales and marketing expenses due to expansion of data business development team and more conferences

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$12.30 mln
$12 mln (1 Analyst)
Q4 EPS
-$0.13
Q4 Adjusted EBITDA
Beat
-$1.02 mln
-$2.48 mln (1 Analyst)
Q4 Gross Margin
41.0%
Q4 Income from Operations
Beat
-$2 mln
-$3.23 mln (1 Analyst)

Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Champions Oncology Inc is $12.00, about 34.6% above its July 22 closing price of $7.85

The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 38 three months ago

Press Release: ID:nACSCgv63a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)